Our Investors

Transport Pharmaceuticals, Inc. is a clinical stage, privately held Delaware Corporation and leader in the convergence of drugs and medical devices for the topical treatment of dermatological conditions. Transport’s late stage lead product, SoloVir™ ETS, represents a potential breakthrough for the treatment of herpes labialis (cold sores), a market with large, unmet medical needs.
Learn More

Partner Opportunities

Transport is an innovative specialty pharmaceutical company, with a dermal product pipeline. Our business model is predicated on integrating commercial partnerships to enhance the value of the large markets we address. We welcome expressions of interest from companies contemplating a partnership with Transport on our clinical-stage opportunities.
Learn More

News & Updates

11.28.07
Transport's Phase 2 Data Show Single Treatment SoloVir™ ETS Significantly Stops Progression of Cold Sore Episodes
Learn More

SoloVir™ ETS

The company’s Lead Product, SoloVir™ ETS, utilizes a proprietary drug formulation and an iontophoretic delivery-device to create a revolutionary paradigm shift in patient initiated treatment of herpes labialis, or cold sores.
Learn More

Frost & Sullivan 2007 Technology Innovation of the Year Award

Frost & Sullivan Award

Transport Pharmaceutical's Receives Coveted Frost & Sullivan Technology Innovation Award.

Learn More